A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Time to clinical progression
Throughout study period
No
Manfred P Wirth, Professor
Principal Investigator
Technical University of Dresden, Germany
Austria: Agency for Health and Food Safety
D6876C00024
NCT00673205
September 1995
August 2008
Name | Location |
---|